While evidence triangulation and complementary analytical methods are well established, there is much less discussion about how they should be integrated and interpreted as a coherent body of evidence.
Using practical examples from vaccine safety and comparative effectiveness research, this webinar will explore the challenge of causal evidence triangulation for pharmacoepidemiology. Specifically, how combining complementary study designs and targeted sensitivity analyses produces robust, regulator-ready causal interpretations in drug safety and effectivenes studies.
Attendees will be able to:
- Explain the principles of evidence triangulation and its role in strengthening causal interpretation
- Describe how complementary study designs and analytical approaches each contribute distinct strengths and limitations through different assumptions and potential source of bias
- Interpret agreement and disagreement between methodological approaches as part of transparent causal interpretation credibility of the evidence
Presenters:
- Moderator: Deborah Layton, PhD
Chief Scientific Officer, PHARMO, part of Lumanity - Abigail Postema, MPhil
Senior Research Manager, RWE, PHARMO, part of Lumanity - Premysl Velek, MSc
Data Scientist, PHARMO, part of Lumanity